Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337418 | 0.94 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1TSHRHPGD | |
| SCHEMBL792692 | 0.89 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1TSHRHPGD | |
| SCHEMBL6643493 | 0.89 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1TSHRHPGD | |
| SCHEMBL3321644 | 0.89 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1TSHRHPGD | |
| SCHEMBL550224 | 0.89 | ALDH1A1 (0.61) | ALDH1A1KMT2AMEN1TSHRHPGD | |
| SCHEMBL31449917 | 0.87 | HPGD (0.68) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL9408055 | 0.86 | CHRM1 (0.61) | ALDH1A1KMT2AMEN1TSHRHPGD | |
| SCHEMBL6182800 | 0.86 | MEN1 (0.52) | ALDH1A1KMT2AMEN1TSHRHPGD | |
| SCHEMBL5943739 | 0.86 | MEN1 (0.52) | ALDH1A1KMT2AMEN1TSHRHPGD | |
| SCHEMBL8263558 | 0.86 | ALDH1A1 (0.59) | ALDH1A1KMT2AMEN1TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023187715-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-10-05 | — | — | WO | disclosed |
| CN-110446495-B | Delta opioid receptor modulating compounds containing 7-membered aza heterocycles and methods of use and preparation thereof | 特维娜有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | Ecstasy LLC (US) | 2023-02-21 | — | — | US | disclosed |
| CN-110662541-B | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2023-02-10 | — | — | CN | disclosed |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2022-12-29 | — | — | US | disclosed |
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | Ecstasy LLC | 2020-06-09 | — | — | US | disclosed |
| CN-110662541-A | Polycyclic amines as opioid receptor modulators | 王晓冬 | 2020-01-07 | — | — | CN | disclosed |
| WO-2018169818-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | WANG XIAODONG (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | Ecstasy LLC | 2018-09-13 | — | — | US | disclosed |
| US-9981960-B2 | Pyrrolidine compound and application as melanocortin receptor agonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-29 | — | — | US | disclosed |
| CN-100569769-C | Compounds with fungicidal activity | MORPHOCHEM AG KOMB CHEMIE (DE) | 2009-12-16 | — | — | CN | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2008118718-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| CN-101155797-A | 1H-benzimidazole-4-carboxamide compounds substituted at the 2-position with a quaternary carbon atom are potent PARP inhibitors | ABBOTT LAB (US) | 2008-04-02 | — | — | CN | disclosed |
| EP-1869011-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1736472-A1 | 2-AMINOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006110816-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| CN-1703412-A | Novel compounds with fungicidal activity | MORPHOCHEM AG KOMB CHEMIE (DE) | 2005-11-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676456-B2 | Polycyclic amines as opioid receptor modulators | OPRM1, OPRL1, OPRK1 | ALDH1A1 825/4885KMT2A 1414/4885MEN1 4685/4885 |
| US-11584765-B2 | Polycyclic amines as sigma receptor modulators | OPRM1, SIGMAR1, OPRK1 | ALDH1A1 1039/4885KMT2A 1818/4885MEN1 4637/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | ALDH1A1 332/4885KMT2A 595/4885MEN1 3097/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | ALDH1A1 2714/4885KMT2A 469/4885MEN1 4512/4885 |
| US-20180258065-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | ALDH1A1 825/4885KMT2A 1414/4885MEN1 4685/4885 |
| US-20220411442-A1 | POLYCYCLIC AMINES AS OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRK1 | ALDH1A1 825/4885KMT2A 1414/4885MEN1 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.